Phase 3 randomized study of TLK286 (Telcyta) [canfosfamide; Telik] versus Doxil/Caelyx [doxorubicin liposomal] or Hycamtin as third-line therapy in platinum refractory or resistant ovarian cancer [ASSIST-1 (Assessment of Survival in Solid Tumors-1)]

Trial Profile

Phase 3 randomized study of TLK286 (Telcyta) [canfosfamide; Telik] versus Doxil/Caelyx [doxorubicin liposomal] or Hycamtin as third-line therapy in platinum refractory or resistant ovarian cancer [ASSIST-1 (Assessment of Survival in Solid Tumors-1)]

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2011

At a glance

  • Drugs Canfosfamide; Doxorubicin liposomal; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASSIST-1
  • Most Recent Events

    • 22 Jul 2011 Last checked against ClinicalTrials.gov record.
    • 22 Jul 2011 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Results published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top